Key result
Simultaneous TAVR and TMVR shows feasibility and sustained 10-month symptom improvement in a case report.
Why the study?
Patients with concomitant severe AS and severe MS with MAC represent a high-risk elderly population with limited treatment options, and simultaneous transfemoral TAVR and transseptal TMVR feasibility needed evaluation.
Does simultaneous transfemoral TAVR and transseptal TMVR improve symptoms in a high-risk patient with severe AS and severe MS with MAC?
Case Report (n=1)
Does simultaneous transfemoral TAVR and transseptal TMVR improve symptoms in a high-risk patient with severe AS and severe MS with MAC?
Simultaneous transfemoral TAVR and transseptal TMVR is a feasible and effective minimally invasive option for high-risk patients with concomitant severe AS and severe MS with MAC.
Supports feasibility in select high-risk cases; leaves open need for prospective data before broader adoption.
Patients with concomitant severe aortic stenosis (AS) and severe mitral stenosis (MS) with mitral annular calcification (MAC) constitute an elderly high-risk population with multiple baseline comorbidities that coexist even before they develop severe valvular dysfunction. Transcatheter mitral valve replacements (TMVR) offer an alternative option for high-risk patient with severe MS with MAC. A simultaneous transfemoral Transcatheter aortic valve replacement (TAVR) and transseptal TMVR is feasible and offers the least invasive approach of management. We are reporting a case of an 83-year-old man with very symptomatic severe AS and severe native MS with associated severe MAC and moderate mitral regurgitation with high STS score who underwent a simultaneous transfemoral TAVR and transseptal TMVR with good results and great improvement in symptoms that was maintained on 10 months follow-up.
No takes yet. Share an insight, caveat, or question.
Fanari et al. (2017) conducted a case report in Severe aortic stenosis and severe mitral stenosis with mitral annular calcification (n=1). Simultaneous transfemoral TAVR and transseptal TMVR using Edward SAPIEN S3 was evaluated on Feasibility and symptom improvement. Simultaneous transfemoral TAVR and transseptal TMVR was feasible and resulted in great improvement in symptoms that was maintained at 10 months follow-up in an 83-year-old man.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: